TargetMol

IITZ-01

Product Code:
 
TAR-T6799
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6799-2mg2mg£97.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6799-5mg5mg£115.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6799-1mL1 mL * 10 mM (in DMSO)£118.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6799-10mg10mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6799-25mg25mg£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6799-50mg50mg£349.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6799-100mg100mg£502.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
IITZ-01 is potent autophagy inhibitor with single-agent anticancer activity ( IC50 of 2.62 μM for PI3Kγ.)
CAS:
1807988-47-1
Formula:
C26H23FN8O
Molecular Weight:
482.523
Pathway:
Apoptosis; Autophagy; PI3K/Akt/mTOR signaling
Purity:
0.99
SMILES:
Fc1ccc(Nc2nc(Nc3ccc(cc3)-c3nc4ccccc4[nH]3)nc(n2)N2CCOCC2)cc1
Target:
Apoptosis; PI3K; Autophagy

References

Guntuku L, Gangasani JK, Thummuri D,et al.IITZ-01, a novel potent lysosomotropic autophagy inhibitor, has single-agent antitumor efficacy in triple-negative breast cancer in vitro and in vivo[J].?Oncogene. 2019 Jan;38(4):581-595.